Get involved

Learn

Newly diagnosed

Resources to help those new to Angelman syndrome.

Learn More

Learn

Donate

Support projects progressing Angelman syndrome research.

donate today

Learn

Fundraise

Start your own fundraising page to help #CureAngelman.

start fundraising

News & Media

News & Media

Australian National Rugby League (NRL) identities Damien Cook, Iosia Soliola, Sam Perrett and Curtis Rona have been using their public profiles to increase awareness into Angelman syndrome.

More media
Enabling Research

Enabling Research

The Global Angelman Syndrome Registry is creating new opportunities, insight and understanding into Angelman syndrome, providing an invaluable tool for facilitating research.

Learn More
Raising Awareness

Raising Awareness

This beautiful video is one of a series produced to illustrate common features of Angelman syndrome and highlights individuality amongst those who have been diagnosed.

Watch More

NEWS FEED

Neuren Australian Clinical Trial

Neuren Australian Clinical Trial

Neuren is a Melbourne-based company at the forefront of efforts to develop effective treatments for rare, paediatric neurodevelopmental disorders, they plan to initiate an Australian clinical trial in Angelman later in 2021. 

Positive Interim Phase 1/2 Data

Positive Interim Phase 1/2 Data

“So far we are seeing rapid improvements in multiple areas, including some kids doing things they’ve never done before, and I don’t believe this rate of progress in development skills has been seen before in Angelman syndrome,” commented Elizabeth M. Berry-Kravis, M.D. investigator in the GTX-102 clinical study.

Angelman Syndrome Biobank

Angelman Syndrome Biobank

If you are a parent of a person with Angelman syndrome in Australia, the Murdoch Children’s Research Institute would like to invite you to participate in the Australian Biobank for Chromosome 15 imprinting disorders.

Roche Clinical trial

Roche Clinical trial

Roche and Genentech (the US member of the Roche group) have recruited the first patient in their Phase 1 clinical trial named "Tangelo" that is targeting AS with an oligonucleotide.